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Abstract 
Background:  TNF weakly inducer of apoptosis (TWEAK) is member of the TNF ligand superfamily. Various data 
support that TWEAK produced by synovial macrophages may contribute to synovitis observed in psoriatic arthritis 
(PsoA). In PsoA, anti‑TNF therapy has been successful in agreement with the key role of TNF in the pathogenesis and 
the generation by PsoA patients of anti‑TNF autoantibodies referred as “beneficial autoimmunity to pro‑inflammatory 
mediators”. However, the role of TNF‑alpha in the regulation of TWEAK modulation of inflammation during PsoA 
remains unknown.
Methods: We have studied level course during anti‑TNF therapy of serum soluble TWEAK. In the same cohort, 
we have investigated the generation of TWEAK‑binding autoantibodies by PsoA patients before and after anti‑TNF 
therapy.
Results: Patients with PsoA had significantly higher serum levels of TWEAK compared with controls [respective 
means (±SEM) were 645 pg/ml (64) and 467 pg/ml (23); (p = 0.006)] but serum soluble TWEAK levels were not cor‑
related with BASDAI (Spearman’s coefficients <0.003, p > 0.05). Our study showed that soluble TWEAK levels were 
not modulated by etanercept therapy [respective Means (±SEM) were 605 (95) (week 12) and 744 (97) (week 24) pg/
ml; (p > 0.23)]. Anti‑TWEAK autoantibodies were detected in 9/13 (69.2 %) PsoA patients at inclusion and only in 3/57 
(5.3 %) healthy blood donors (p < 0.0001). These circulating antibodies were persistent in PsoA patients and detected 
at similar levels during etanercept therapy. Moreover we showed that they had a down regulating effect on CCL‑2 
secretion by endothelial cells stimulated by rh TWEAK in vitro.
Conclusion: Our study revealed that during psoriatic arthritis (1) serum TWEAK was up regulated and (2) TWEAK‑
binding autoantibodies are generated. Both parameters were not influenced by anti‑TNF therapy and persisted at 
high levels during anti‑TNF therapy. For the first time we described here TWEAK‑binding IgG autoantibodies with a 
down regulating effect on CCL‑2 secretion by endothelial cells stimulated by rh TWEAK in vitro. Finally, our results sug‑
gest that TWEAK may be involved in PsoA pathogeny.
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Sud‑Méditerranée V” with the registration number: 2011‑002954‑29, and French health minister registration number 
AFSSAPS A110784‑42 obtained the 08/22/2011. This clinical trial is registered in Clinical trial.gov under the number: 
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Background
TNF weakly inducer of apoptosis (TWEAK) is a type 
II-transmembrane protein, member of the TNF ligand 
superfamily that can be cleaved to function as a soluble 
cytokine [1]. Depending on target cell type, TWEAK trig-
gers multiple cellular responses ranging from modulation 
of inflammation to cell death when it binds to its main 
receptor, Fn14. Our team has been the first to describe 
pro-inflammatory effects of TWEAK during central nerv-
ous system inflammation and to show protective effect of 
TWEAK/Fn14 blockade in a multiple sclerosis murine 
model [2–4]. Similarly, inhibition of TWEAK has been 
shown to reduce systemic inflammation in other models 
of autoimmune/chronic inflammatory diseases such as 
rheumatoid arthritis (RA) or systemic lupus erythemato-
sus [5, 6]. TWEAK is lowly expressed in steady state con-
ditions but during both acute and chronic inflammation 
TWEAK expression is highly upregulated in many tissues 
and peritoneal macrophages [3, 7–9]. Various data sup-
port the possibility that TWEAK produced by synovial 
macrophages may contribute to chronic synovitis in ani-
mal models and in humans [10–12]. TWEAK may be an 
actor of inflammatory arthritis pathogenesis by promot-
ing inflammation and angiogenesis. Psoriatic arthritis 
(PsoA) is a complex and multifaceted chronic inflamma-
tory disease that involves synovial tissue, entheses, skin 
and nails. This frequent inflammatory arthritis is known 
to adopt a variable clinical course that may range from 
mild symptoms requiring minimal intervention to a dis-
abling course leading to loss of function for which treat-
ment strategies targeting inflammation are recommended 
[13–15]. In this context, anti-TNF therapy has been suc-
cessful in PsoA concordant with the key pro-inflamma-
tory role of TNF in the pathogenesis of this disease and 
the generation by PsoA patients of neutralizing anti-TNF 
autoantibodies has been referred as “beneficial autoim-
munity to pro-inflammatory mediators”. In 2010, Van 
Kuijk et al. have described a high expression of TWEAK 
and Fn14 in the inflammatory synovial of PsoA and RA 
patients and have noted the persistence of this expres-
sion after anti-TNF therapy [12]. However a direct role 
of TNF-alpha inhibition in the regulation of TWEAK 
expression or biological effects remains unknown. Ben-
eficial effects of anti-TNF therapy in inflammatory arthri-
tis could be mediated in part by blocking TNF produced 
by synovial macrophages but also in part by modulating 
TWEAK which is also produced by these cells. To assess if 
anti-TNF therapy affects TWEAK modulation of inflam-
mation during PsoA, we have studied level course during 
anti-TNF therapy of serum soluble TWEAK. In the same 
cohort, we have investigated the generation of TWEAK-




Twenty-one patients with PsoA who attended the Divi-
sion of Dermatology and Rheumatology of the Aix-
Marseille University Hospital were involved in this 
prospective study. For inclusion the patients have been 
examined by both a dermatologist and a rheumatolo-
gist. The PsoA was diagnosed according to the CASPAR 
(ClASsification of Psoriatic ARthritis) group criteria [15]. 
All the included patients fulfilled the later criteria and 
were eligible at time of inclusion for anti-TNF therapy 
[16]. Then, all the patients received a dose of 50 mg once 
a week of etanercept by subcutaneous injection. Blood 
samples were collected by venous puncture for each 
patients at the inclusion time and at 12th and 24th weeks 
of etanercept therapy. Among these 21 patients, thirteen 
(7 women and 6 men) have received the complete clinical 
and biological follow-up as determined in our research 
protocol. After blood centrifugation, serum samples have 
been collected, aliquoted and rapidly stored at −80  °C 
until analysis. Control blood samples were obtained from 
57 healthy blood donors with no evidence of autoim-
mune/chronic inflammatory disease (38 women and 19 
men). At the time of blood sample collection for PsoA 
patients, the erythrocyte sedimentation rate (ESR) and 
serum C reactive protein concentration were evalu-
ated and the disease activity was assessed according to 
the BASDAI [17]. Responders were defined as patients 
with a BASDAI at 12th decreased at least of 50 % or two 
points in comparison with BASDAI at the beginning of 
the treatment. Informed consent was obtained from 
all patients. The procedures followed were approved by 
the local Ethics Committee (ref CPP 2011-002954-29, 
ref AFSSAPS A110784-42, Clinical trial.gov number: 
NCT02164214).
Quantification of soluble TWEAK and CCL‑2 by ELISA
Serum concentrations of soluble TWEAK were deter-
mined using commercial ELISA kit purchased from 
Bender Medsystems, Vienna, Austria, according to the 
manufacturer’s protocol. The limit of detection of the 
test was 16  pg/ml. Culture supernatant concentrations 
of soluble CCL-2 were determined using commercial 
ELISA kit purchased from Peprotech (Neuilly sur Seine, 
France) according to the manufacturer’s instructions. The 
limit of detection of the test was 8 pg/ml. The absorbance 
was read using a spectrophotometer (Infinite™ TECAN, 
Mannedorf, Switzerland) at a wavelength of respectively 
450 and 405 nm.
Cell culture and reagents
Human Embryonic Kidney 293 cells (HEK293) and 
Human umbilical vein endothelial cells (HUVECs) were 
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obtained from ATCC (Molsheim, France) and were 
respectively cultivated in DMEM with 10 % FCS and 1 % 
penicillin–streptomycin (Invitrogen, Illkirch, France) and 
EBM-2 basal medium supplemented with EGM-Plus bul-
let kit (Lonza, Basel, Switzerland). Recombinant human 




Recombinant human TWEAK (300 ng) was blotted dur-
ing a 15  % sodium dodecyl sulphate polyacrylamide gel 
electrophoresis using a Mini-protean system (Bio-Rad, 
Hercules, CA, USA) and transferred onto nitrocellu-
lose Hybond-C membrane (Amersham Biosciences, 
Buckinghamshire, UK). The nitrocellulose membrane 
was then cut into 0.5  cm-wide strips. After blocking, 
strips were incubated with 1:50 diluted patient serum at 
4  °C overnight. After washing, membranes were incu-
bated with a biotin-conjugated anti-human IgG anti-
body (Jackson Immunoresearch, West Grove, PA), and 
then with alkaline phosphatase conjugated strepta-
vidin (Jackson Immunoresearch, West Grove, PA). 
Finally, the strips were incubated with a revelation solu-
tion containing nitro-blue tetrazolium and 5-bromo-
4-chloro-3′-indolyphosphate (both from Euromedex, 
Souffelweyersheim, France). In case of positivity at the 
screening dilution, serum of patients have been further 
diluted up to 1:1000.
Indirect Immunofluorescence
HEK 293 cells were plated in 6-well plates in DMEM 
Glutamax, 10 % FCS, 1 % penicillin/streptomycin (Ther-
moFisher scientific, Waltham, MA, USA). The cells were 
transfected with Jet Pei transfection reagent (Ozyme, 
Saint-Quentin en Yvelines, France) and pJST773-45-fl-
hu-TWEAK plasmid coding for TWEAK, a kind gift from 
Linda Burkly, (Biogen Idec, Cambridge, MA, USA) which 
contains full length human TWEAK amino acid 1-248 in 
the mammalian expression vector CH269. The full length 
human TWEAK coding sequence was generated by PCR 
using full length TWEAK cDNA as template and prim-
ers containing Not1 sites. The PCR fragment was cloned 
into the Not1 site of CH269 in the proper orientation and 
the DNA sequence confirmed. The parental expression 
vector is a derivative of pCEP4 (Invitrogen). As such, the 
plasmid pJST773 expresses TWEAK under the control of 
the CMV promoter and SV40 polyadenylation sequence 
and is capable of episomal replication due to the pres-
ence of the EBV oriP. The plasmid is ampicillin resistant 
in E. coli. Twenty-four hours after transfection, cells were 
plated on 8-wells microscope slides (ThermoFisher sci-
entific, Waltham, MA, USA). At confluence, the medium 
was replaced by OptiMEM (ThermoFisher scientific, 
Waltham, MA, USA) during 12  h and then cells were 
fixed by PFA 4  %. After blocking, slides were incubated 
with 1:50 diluted patient serum in PBS BSA 3 % at room 
temperature. After washing, slides were incubated with 
FITC-conjugated anti human IgG (Biorad, Hercules, CA, 
USA) for 1 h at room temperature. Nuclei were stained 
with Hoechst 33342 nucleic acid stain (ThermoFisher 
scientific, Waltham, MA, USA). Sections were mounted 
using Prolong Gold anti fading reagent (ThermoFisher 
scientific, Waltham, MA, USA). Images were acquired 
and processed using a light-emitting diode (LED) fluo-
rescence microscope DM1000 (Leica, Wetzlar, Germany) 
equipped with a digital camera (Fraen, Reading, MA, 
USA).
Affinity purification of TWEAK‑binding IgG
IgGs from serum of one TWEAK-binding antibody posi-
tive PsoA patient were purified on Affi-Gel Protein A 
MAPS II columns (Bio-Rad, CA, USA) in accordance 
with the instructions of the manufacturer. This patient 
had high titers of TWEAK-binding antibody as detected 
by immunoblotting experiments and the serum used for 
purification was obtained at the time of inclusion before 
etanercept treatment. IgG eluted fraction was concen-
trated with Amicon Ultra 15  mL (Millipore, Molsheim, 
France) before being applied to the TWEAK affinity 
column made from Pierce NHS activated Agarose resin 
columns (ThermoScientific (Massachusetts, UE) and rh 
TWEAK. Purified total serum IgG were incubated dur-
ing 2 h at room temperature on the column and then the 
TWEAK column was washed with PBS (0,1 M phosphate 
sodium, 0,15 M NaCl pH 7,2) before bound anti-TWEAK 
IgG were eluted by using 0.1 M glycine–HCl buffer (pH 
2.5) and were directly neutralized with 1 M Tris (pH 9). 
TWEAK-binding IgG were concentrated with Amicon 
Ultra 4 mL (Millipore, Molsheim, France) and IgG con-
centration of the fraction was quantified by immuno-
nephelometry on a Siemens Healthcare analyzer (BN 
Prospec, Siemens Healthcare, Saint Denis, France). The 
specificity of the eluted material was further confirmed 
by its ability to bind rh TWEAK in immunoblotting 
experiment.
Evaluation of TWEAK‑binding IgG effect on CCL‑2 secretion 
by endothelial cells
Human Umbilical Vein Endothelial Cells were incubated 
for 24  h with rh TWEAK (100  ng/ml) or not (medium 
condition) in a serum-free culture medium. During this 
exposure, in other wells, cells were also co-incubated 
with a commercially available goat polyclonal block-
ing anti-TWEAK antibody (R&D systems, Minneapolis, 
MN, USA) (5 µg/ml) or with purified human serum IgG 
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(Sigma Aldrich (Saint Louis, MO, USA) (50 ng/ml) (nega-
tive for TWEAK-binding IgG homemade test by western 
blotting) (both control conditions) or with purified PsoA 
patient TWEAK-binding IgG (50  ng/ml). Supernatants 
were collected, centrifuged and stored at −80  °C until 
quantification of CCL-2 by ELISA. All samples were ana-
lyzed in duplicate.
Statistical analysis
Sensitivity was measured as the probability of a positive 
result in a patient with PsoA. Specificity was measured as 
the probability of a negative result in a non-PsoA patient. 
All statistical analyses were performed using Graph-
Pad Prism® Program Version 6.05 (GraphPad Software 
Inc., San Diego, CA, USA). Results of soluble TWEAK 
or CCL-2 (mean  ±  standard error of the mean) repre-
sent duplicate measurements. Groups were compared 
using the Mann–Whitney nonparametric U-test or inde-
pendent t test as appropriate. Spearman’s rank correla-
tion coefficient was used to test the correlation between 
serum TWEAK or anti-TWEAK antibodies and other 
parameters. The p values less than 0.05 were considered 
statistically significant.
Ethics section
This clinical trial was approved by the local Ethics 
Committee “Comité de Protection des Personnes Sud-
Méditerranée V” with the registration number: 2011-
002954-29, and French minister registration number 
AFSSAPS A110784-42 obtained the 08/22/2011. This 




Table  1 shows the patient characteristics of the PsoA 
patient cohort. Men and women have been included in 
equal numbers. Serum of 57 healthy blood donors were 
also analyzed. The mean age of these control subjects 
(19 men/38 women) was 41.4  years (range from 27 to 
55  years). Most PsoA patients had longstanding disease 
since 9 patients out of 13 had a disease duration ≥2 years. 
Ten patients displayed comparable low ESR while the 
3 other one had ESR ≥15  mm/h. The CRP levels were 
found above 5 mg/l for 6 patients. The BASDAI at base-
line ranged from 3 to 8 and 10 out of 13 patients were 
responders to etanercept as indicated by the decrease of 
their BASDAI at 12 weeks of etanercept administration.
Increased levels of serum TWEAK during PsoA before and 
after anti‑TNF treatment
Serum TWEAK levels were significantly higher in PsoA 
patients at baseline (645 ± 64 pg/ml) and after 24 weeks 
of etanercept administration (744  ±  97  pg/ml) than 
in healthy controls (467 ± 23 pg/ml; p < 0.05) (Fig. 1a). 
During anti-TNF therapy, serum TWEAK levels are not 
statistically modified in comparison with baseline levels 
(645 ± 64 pg/ml) neither at 12th week (605 ± 95 pg/ml; 
p =  0.44) nor at 24th week (744 ±  97 pg/ml; p =  0.55) 
(Fig.  1a). The evolution profile of serum TWEAK levels 
during anti-TNF therapy differs for each patient to others 
as represented in Fig. 1b.
No evidence for relationship of serum TWEAK levels 
to response to anti‑TNF treatment
All the PsoA patients of our study received etanercept 
treatment after the initial blood sampling and 10 of these 
(76.9  %) achieved responder criteria at the 12th week 
of etanercept treatment. When patients were divided 
into responders and nonresponders, the sample size of 
the nonresponder group was too low for applying sta-
tistical tests but we have observed that there was no 
obvious difference neither in baseline serum TWEAK 
levels (responders: 675  ±  72  pg/ml vs. nonrespond-
ers: 547 ± 145 pg/ml) nor in 12th week serum TWEAK 
levels (responders: 704 ±  114 pg/ml vs. nonresponders: 
877 ± 192 pg/ml) between the two groups (Fig. 2). More-
over neither responder (baseline: 675 ± 72 pg/ml vs 12th 
week: 704  ±  114  pg/ml) nor nonresponders (baseline: 
547 ±  145  pg/ml vs. 12th week: 877 ±  192  pg/ml) dis-
played a significant modification of serum TWEAK levels 
between baseline and 12 weeks of etanercept administra-
tion (Fig. 2).
Description for the first time of TWEAK‑binding 
autoantibodies generated during PsoA
We were able to detect and describe for the first time 
anti-TWEAK autoantibodies in the serum of PsoA 
patients by using western blot (Fig.  3a) and/or indirect 
immunofluorescence (Fig.  3b). Nine out of 13 patients 
(corresponding to 28 samples out 39) (69.2  %) were 
Table 1 Characteristics of patients with PsoA
Characteristics PsoA
(n = 13)
Age (years) (range) 50.9 (40–66)
Men/women 6/7
Disease duration (years) (range) 6 (1–22)
BASDAI at baseline (range) 5.8 (3–8)
ESR (mm/h) at baseline (range) 14.5 (1–49)
CRP (mg/l) at baseline (range) 15.1 (1–60)
BASDAI at 12th week (range) 3.7 (0–7.1)
BASDAI at 24th week (range) 3.4 (0.4–8.2)
Responders/non responders 10/3
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positive for the western blot screening test while only 3 
healthy controls out of 57 (5.3 %) were positive for this 
test (p  <  0.0001). The sensitivity and the specificity of 
the western blot analysis for the diagnosis of PsoA were 
respectively 69.2 and 94.7  %. The healthy controls dis-
played low titers of auto-antibodies since they were all 
positive only at the screening dilution (1:50) while anti-
body titers in PsoA positive patients ranged from 200 
to above 1000 (Fig.  4). Results of western blot agreed 
with IFI in 29/39 (74.3  %) samples and 7 samples were 
only positive for western blot while 3 were positive with 
IFI only. As shown in Fig.  4, during anti-TNF therapy, 
anti-TWEAK antibodies were persistent in the nine 
patients who were positive at baseline (Fig.  4). We did 
not observe the appearance of such auto-antibodies after 
the initiation of anti-TNF therapy in patients who were 
negative at baseline. In the group of the nine patients 
displaying anti-TWEAK antibodies in their serum, 
titers varied during anti-TNF therapy but the sense of 
variation (decrease or increase) was different from each 
patient to the others (Fig. 4).
Correlation studies of serum TWEAK levels or anti‑TWEAK 
antibody levels with clinical and biological parameters
In patients with PsoA, we found a significant inverse cor-
relation (r = −0.58, p =  0.03) between serum TWEAK 
levels at baseline and disease duration (Fig.  5). In the 
same patients, we did not observe correlation between 
Fig. 1 Serum TWEAK levels in patients with PsoA (n = 13) and controls (n = 57). Serum samples have been collected at baseline and 12 and 
24 weeks after the initiation of etanercept therapy. TWEAK levels have been evaluated with a commercially available ELISA kit. a Median is indicated 
for each group as a black line in the box. b Evolution over time of TWEAK levels is represented for each patient
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serum TWEAK levels at baseline and other parameters 
such as BASDAI at baseline (r  =  0.12, p  =  0.67), anti-
TWEAK antibody titers at baseline (r = −0.13, p = 0.56) 
(Fig. 5) or ESR or CRP (data not shown). Anti-TWEAK 
antibody titers were not correlated with BASDAI nei-
ther at baseline (r = −0.11, p = 0.60) (Fig. 5) nor at 12th 
nor at 24th week during anti-TNF therapy (data not 
shown). Even if the sample size of nonresponders was too 
low for applying a statistical analysis, we have observed 
that anti-TWEAK antibody prevalence in responders 
(7/10 i.e. 70 %) and not responders (2/3 i.e. 66.6 %) were 
comparable.
Down regulation by TWEAK‑binding IgGs of the in vitro 
endothelial CCL‑2 secretion
Inflammation is a key component of PsoA and leuko-
cyte transmigration across the endothelium under the 
chemokine CCL-2 gradient is a crucial step of inflam-
mation. To evaluate in vitro biological effects of purified 
PsoA patient TWEAK-binding IgG we have analyzed the 
impact of this antibody exposure on CCL-2 secretion by 
endothelial cells stimulated by rh TWEAK. We found 
that incubation of these cells with TWEAK-binding 
IgG down regulated their CCL-2 secretion under a 24 h 
TWEAK exposure (10 881 pg/ml with patient TWEAK-
binding IgG versus 15  647  pg/ml without patient 
TWEAK-binding IgG; p < 0.0001) (Fig. 6).
Discussion
Since TWEAK may be involved in PsoA pathogenesis 
by promoting inflammation and angiogenesis, we have 
investigated if beneficial effects of anti-TNF therapy in 
PsoA are mediated in part by blocking TWEAK produced 
by synovial macrophages. In the present study we have 
shown increased levels of serum TWEAK during PsoA at 
baseline. We have demonstrated that the levels of solu-
ble TWEAK were not modulated by anti-TNF treatment 
and found no evidence for relationship between serum 
TWEAK levels and response to anti-TNF treatment. 
We have also described for the first time that TWEAK-
binding IgG autoantibodies were generated during PsoA 
and were persistent at elevated titers in patients even if 
an etanercept therapy was conducted. In patients with 
PsoA, we found a significant inverse correlation between 
serum TWEAK levels at baseline and disease duration 
Fig. 2 Relationship of serum TWEAK level to response to anti‑TNF 
treatment. Responders (n = 10) are defined as patients with a 
minimal decrease of BASDAI of 50 % or 2 points at 12th week of treat‑
ment. Black lines in the box indicate the median of values
Fig. 3 Detection of serum anti‑TWEAK auto‑antibodies. a Western 
blot assay using recombinant human TWEAK. Line 1 Positive patient 
with PsoA. Line 2 Negative patient with PsoA. Line 3 Negative control 
serum. On line 1, 2 and 3, sera are 1:50 diluted. Line 4 Positive control 
based on revelation with a commercially available polyclonal anti‑
TWEAK antibody. Line 5 Negative control based on serum omission. 
b Immunofluorescence test. Serum are incubated on wild‑type HEK 
cells and on TWEAK‑transfected HEK cells. Membrane and cytoplas‑
mic fluorescence staining patterns specifically observed with an 
anti‑TWEAK antibody positive patient serum only on the transfected 
wells are indicated by white arrows
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but not with BASDAI. Anti-TWEAK antibody titers 
were neither correlated with BASDAI nor with the ability 
to respond to anti-TNF therapy. Finally we showed that 
TWEAK-binding IgG down regulated CCL-2 secretion 
by endothelial cells stimulated by rh TWEAK.
Psoriatic arthritis (PsoA) is a heterogenous chronic 
inflammatory joint disease belonging to the spondy-
loarthropathy family that can have devastating effect on 
patient function and quality of life equivalent of those 
observed during rheumatoid arthritis (RA) [18]. TNF 
inhibitors have shown to work well in PsoA for axial and 
peripheral arthritis and the other manifestations of the 
disease such as cutaneous lesions of psoriasis, enthesitis 
and dactylitis [19]. However, given the considerable het-
erogeneity in the clinical manifestations in PsoA, rang-
ing from self-limiting to chronic severe and progressive 
forms and concerns over safety and cost, the use of TNF 
blockers should be restricted to patients with an optimal 
risk–benefit ratio. However, validated biomarkers for 
predicting progression are lacking and early detection of 
candidates for TNF blockade remains difficult. TWEAK 
is a member of the TNF ligand family that functions 
mainly as a secreted cytokine like TNF-α [1]. TWEAK 
regulates a number of biological processes including 
cellular proliferation, angiogenesis and cytokines secre-
tion through Fn14 [3, 20–22]. Activation of TWEAK/
Fn14 signaling has been involved in several processes of 
injury and inflammation that result in end-organ dam-
age including RA [23]. In 2008, Park et  al. published 
interesting data showing that serum levels of TWEAK 
were significantly elevated in patients with RA, reflected 
disease activity and short-term response to etanercept 
treatment [24]. Only two publications about TWEAK 
involvement during PsoA are available [12, 25]. In 2009, 
Van Kujik et  al. have found that TWEAK and its main 
receptor Fn14 were abundantly expressed in the inflamed 
synovium of RA and PsoA patients. Moreover they have 
demonstrated that this expression was persistent after 
TNF blockade by infliximab [12]. These data agreed 
with our results showing that another TNF blocker, 
Fig. 4 Evolution over time of serum anti‑TWEAK auto‑antibody titers in positive PsoA patients. a Titers of auto‑antibodies have been obtained by 
serial dilutions (1:50, 1:100, 1:200, 1:400, 1:800, 1:1000) of screening positive samples (n = 9) tested with our home made western blot assay using 
recombinant human TWEAK. Samples with titers above 1000 are indicated by a grey arrow. b The images of each membrane according to the serial 
dilution are represented for a patient exhibiting TWEAK‑binding IgG at a titer of 800
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Fig. 5 Relationship of serum TWEAK levels or anti‑TWEAK antibody levels to disease duration and BASDAI. Spearman’s correlation analysis was used 
to test for correlations. Spearman coefficients (r) and p values (p) are indicated in each plot
Fig. 6 Down regulation by TWEAK‑binding IgGs of the in vitro endothelium CCL‑2 secretion. ELISA analysis of CCL‑2 levels in the supernatants of 
HUVECs stimulated by TWEAK (100 ng/ml) or not (medium) and co‑incubated with a commercially available goat polyclonal blocking anti‑TWEAK 
antibody (5 µg/ml) or with purified human serum IgG negative for TWEAK‑binding IgG test (50 ng/ml) or with purified PsoA patient TWEAK‑binding 
IgG (50 ng/ml). Note the downregulation of the increased secretion of CCL‑2 under TWEAK exposure when cells are incubated with purified PsoA 
patient TWEAK‑binding IgG. *p < 0.01, **p < 0.001, ***p < 0.0001 according to Student’s t test
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etanercept, doesn’t have drastic effect on TWEAK 
expression. Later, Xia et al. investigated serum TWEAK 
levels in PsoA patients in comparizon with healthy con-
trols [25]. They found that PsoA patients presented sig-
nificantly more elevated serum TWEAK concentrations 
than controls. Upon concluding remarks, our work is in 
accordance with this study. However, we found with the 
same commercially available ELISA kit 10-fold higher 
values than Xia et al. for serum TWEAK both in patients 
and controls. We have recently discussed the point that 
the most important criticism concerning TWEAK evalu-
ation in autoimmune/chronic inflammatory diseases is 
the difficulty in obtaining consensual ranges for normal 
values of soluble TWEAK [26]. Reagents for the assess-
ment of TWEAK levels are now commercially available 
for research purposes only. However, standardization 
of the proposed kits is absolutely required all the more 
because free soluble TWEAK is a “sticky” protein diffi-
cult to manipulate based on experience from our team. 
We have also noted in our experience that it is very 
important to take particular care of pre-analytical phase 
to avoid TWEAK degradation in  vitro and to obtain 
reproducible quantifications of the soluble protein. In the 
study of Xia, a moderate correlation was found between 
serum TWEAK levels and disease activity of PsoA. An 
explanation of the discrepancy of results of the two teams 
could be the use of different evaluation scores: 28-joint 
count Disease Activity Score (DAS 28) for Xia et al. and 
BASDAI for our team.
In the present study we described a new type of anti-
cytokine autoantibodies occurring during chronic 
inflammatory disease. Anti-cytokine antibodies are 
described in disparate conditions and situations (can-
cers, infectious diseases, immunodeficiency…) and may 
cause a wide variety of potentially life threatening ill-
nesses [27–29]. Anti-cytokine antibodies against TNF-α 
and interferon-α, two of the key players in the pathogen-
esis of psoriasis, have been related in psoriasis patients 
by Bergman et  al. The authors concluded then these 
antibodies could be an epiphenomenon or might play 
a role in modulating the ongoing inflammatory process 
[30]. In our work, we propose that auto-immunity against 
another key player in the genesis of the disease, TWEAK, 
also take place during PsoA. The antibodies we described 
were of IgG isotype and circulated at high titers in the 
patient sera (and at low titer in controls) suggesting 
their belonging to auto-immune antibodies rather than 
to natural antibodies. We have investigated the perfor-
mances of these antibodies for PsoA diagnosis and found 
interesting sensitivity (69.2  %) and specificity (94.7  %) 
but these results may be modulated by the nature of 
the control group we have included for the calculation 
of these parameters. We compared PsoA group with a 
healthy blood donor group but another control group 
with “other inflammatory diseases” was probably lack-
ing. For detecting anti-TWEAK antibodies we developed 
two immunoanalysis methods, western blot and indi-
rect immunofluorescence. Not surprisingly, we observed 
some discrepancies between the two approaches. Both 
methods were based upon a presentation of the antigen 
on a solid-phase but some differences in its recognition 
by patient antibodies can occur for following reasons: (1) 
antigen source in western blot was a commercial recom-
binant form of human TWEAK produced in E. coli, a 
protein without post-translational modifications, while 
TWEAK used in IFI was synthetized by human trans-
fected cells and then post-translationally modified, (2) 
experimental conditions of western blot favored antigen 
denaturation and loss of conformational epitopes while 
IFI allowed conservation of native configuration of the 
antigen, (3) antigen expression level was relatively con-
stant during western blot experiments while it varied 
with cell transfection ratio in IFI.
Our study revealed the occurrence of TWEAK-binding 
antibodies during PsoA. Their potential pathogenic role 
in PsoA remains to be examined in detail but we propose 
in this work that they participate in down modulating the 
ongoing inflammatory processes by acting on chemokine 
secretion, especially CCL-2, by endothelial cells and 
then on leukocyte chemotaxis and recruitment on the 
inflammatory sites. These antibodies may have a protec-
tive action in PsoA pathogenesis. However prospective 
in vivo studies are needed to evaluate the role of TWEAK 
and TWEAK-binding antibodies during PsoA.
Conclusion
Our study revealed that during PsoA (1) serum TWEAK 
was up regulated and (2) TWEAK-binding autoantibod-
ies are generated. Both parameters were not influenced 
by anti-TNF therapy and persisted at high levels during 
anti-TNF therapy. For the first time we described here 
TWEAK-binding IgG autoantibodies with a down regu-
lating effect on CCL-2 secretion by endothelial cells stim-
ulated by rh TWEAK in vitro. Finally, our results suggest 
that TWEAK may be involved in PsoA pathogeny.
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